ion exchange reported a significant contraction in profitability for the first quarter of FY27, with consolidated net profit after tax (PAT) plunging 93.6% year-on-year to ₹31 Mn. This decline occurred even as the company’s operating income grew by 20.1% to ₹7,005 Mn, highlighting a severe divergence between top-line growth and bottom-line performance. The earnings pressure stems from elevated costs associated with legacy engineering projects, geopolitical disruptions affecting the specialty chemicals segment, and increased depreciation following the commissioning of its new Roha manufacturing facility.

The company submitted its earnings presentation to the BSE and NSE on August 10, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Management highlighted that while revenue growth was robust across multiple segments, margin expansion was hindered by structural cost increases and execution challenges in specific contract portfolios. The standalone PAT also fell sharply by 75.7% to ₹114 Mn, reflecting similar operational headwinds at the parent company level.

Financial Performance Overview

The financial results for Q1FY27 reveal a stark contrast between revenue generation and profit retention. Consolidated operating EBITDA declined 49.3% year-on-year to ₹318 Mn, causing EBITDA margins to compress by 622 basis points to 4.54%. In comparison, the standalone EBITDA dropped 45.4% to ₹307 Mn, with margins falling 602 basis points to 4.83%.

Depreciation expenses surged significantly, rising 77.2% to ₹218 Mn on a consolidated basis, primarily due to the addition of fixed assets from the Roha plant. Finance costs also increased substantially, jumping from ₹26 Mn to ₹90 Mn, further squeezing the profit before tax (PBT), which fell 89.3% to ₹70 Mn.

Segmental Analysis

The company’s performance varied across its five reporting segments. Treatment Solutions saw revenue growth of 14%, but margins remained under pressure due to legacy projects. Industrial Products demonstrated strong resilience, with revenue up 14% and EBIT margins expanding from 5.53% to 11.89%, driven by robust demand for standard water treatment solutions and membranes.

Specialty Chemicals recorded a 21% revenue increase to ₹2,297 Mn; however, EBIT margins contracted to 9.71% from a previous high, attributed to geopolitical impacts and higher costs linked to the Roha facility capex. Consumer Products emerged as a bright spot, with revenue surging 33% to ₹1,124 Mn, although the segment remained loss-making with an EBIT of -0.27%. Lifecycle Services grew revenue by 25%, with EBIT margins improving from 8.55% to 10.56%.

What the Numbers Show

A critical observation from the Q1FY27 data is the widening gap between revenue growth and profitability. While the company successfully expanded its top line by over 20%, the inability to translate this into proportional EBITDA growth indicates persistent structural cost issues. The 622-basis-point drop in consolidated EBITDA margins suggests that current pricing power is insufficient to offset the combined impact of legacy project inefficiencies and new capex-related depreciation. Investors should monitor whether the upcoming liquidation of the existing backlog and ramp-up of volumes from the Roha plant can restore margin health in subsequent quarters.

Order Book and Future Outlook

As of June 30, 2026, the total order book stood at approximately ₹24,730 Mn, including engineering projects valued at ~₹21,820 Mn. The bid pipeline remains substantial at ~₹97,770 Mn, providing visibility for future revenue streams. Management identified key growth drivers as the liquidation of existing backlogs, expansion in overseas markets, and increased offtake from the newly commissioned Roha plant. The company aims to strengthen its international presence and improve working capital cycles to mitigate the impact of geopolitical uncertainties.

Ion Exchange (India) Limited has submitted its investor presentation for the financial year ending March 31, 2027 (FY27), to the Bombay Stock Exchange and the National Stock Exchange of India Limited on August 10, 2026. The filing, made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, outlines the company’s strategic roadmap, including a restructuring of its financial reporting segments and major capacity expansion initiatives across its manufacturing footprint.

The company announced a transition from its existing three-segment reporting structure—Engineering, Chemicals, and Consumer Products—to a more granular five-segment model. This change aims to provide greater clarity on revenue streams and operational performance. The new segments are Treatment Solutions, Industrial Products, Lifecycle Services, Specialty Chemicals, and Consumer Products. This restructuring reflects the company’s evolving business mix, which now places significant emphasis on services and specialty chemical offerings alongside traditional engineering and consumer goods.

Strategic Capacity Expansions

The presentation details aggressive scaling plans in core manufacturing areas to strengthen global competitiveness. Key investments include:

In Ankleshwar, Gujarat, the company is expanding conventional resin capacity and has established India’s first Non-Solvent Resin manufacturing facility. Additionally, an Integrated Spent Acid Recovery system has been implemented to enable circular manufacturing, described as a global first. For pharma resins, the expansion includes enhanced FDA-approved manufacturing capacity and the introduction of new Weak Acid Cation and Acrylic Anion resin grades.

Global Manufacturing and R&D Footprint

Ion Exchange continues to leverage its six-decade legacy in water treatment technology, supported by over 50 patents and 100+ products launched since its founding in 1965. The company operates multiple Centers of Excellence, including a Technology Centre in Vashi, Maharashtra, and a Chemical Centre in Patancheru, Telangana. These facilities focus on systems design, application testing, resin development, and microbiology research.

The company’s global manufacturing network spans India, Saudi Arabia, Portugal, UAE, South Africa, Indonesia, and Bangladesh. In Goa, the Verna facility serves as a Centre of Membrane Excellence, supporting the production of Reverse Osmosis (RO), Ultrafiltration (UF), Nanofiltration (NF), and Membrane Bioreactor (MBR) systems. The UAE assembly unit is ICV certified, reinforcing the company’s presence in the Middle East.

Emerging Solutions and Digital Integration

The FY27 presentation highlights growth in emerging solution categories, including Brine Valuation, Lithium Extraction, New Energy Solutions, Semiconductor Solutions, Data Center Solutions, and Digital Solutions. Specific initiatives include:

• Lithium Extraction: Recovering lithium from battery waste and brines using advanced membrane and resin solutions.
• Semiconductors & Data Centers: Providing Ultra Pure Water (UPW) systems and condensate polishing for high-purity requirements.
• Digital Assets: Deploying AI-Powered IonSiTE Remote Asset Performance Management (APM) and Digital Twins for oil & gas, utilities, infrastructure, and data centers.

Consumer and Services Growth

In the consumer segment, the ZeroB brand aims to expand its alkaline and hydrogen water portfolio while improving margins through product optimization. The company plans to scale adjacent categories such as On-The-Go (OTG) purifiers, heat pumps, and pressure pumps. ZeroB currently serves more than 4 Lacs customers through a nationwide service network covering 700+ cities with 2,000+ trained engineers.

The Lifecycle Services division, established as India’s most comprehensive platform for water and wastewater treatment, offers Operations & Maintenance (O&M), rehabilitation, spares, BOO/BOOT/WaaS models, and remote monitoring. The division holds ISO certification and operates NABL and RBNQ certified laboratories.

What the Numbers Show

The shift to five reporting segments signals a strategic pivot towards higher-margin services and specialty chemicals, rather than relying solely on capital-intensive engineering projects. By explicitly separating Specialty Chemicals and Lifecycle Services, Ion Exchange is highlighting recurring revenue streams and high-value niche products. The ambitious target of increasing pharma resin market share from 3.5% to 17% suggests a strong belief in the domestic pharma sector’s growth and the company’s ability to capture larger volumes through localized, FDA-compliant manufacturing.